ZYME
Zymeworks Inc.$28.11-0.45 (-1.56%)Prev Close$28.56·MCap$2.10B·P/E—·Vol237.5K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
9
$8.06M
◆
Net Activity
Net Seller
$8.06M
●
Active Insiders
4
last 12 mo
Over the past 12 months, insider activity at Zymeworks Inc. (ZYME) has been exclusively selling, with 0 insider purchases totaling $0.00 and 9 insider sales totaling $8.06M. The most recent insider transaction was by Hollywood Mark (officer: EVP & Chief Operating Officer), who sold $138.8K worth of shares on Jan 13, 2026. Zymeworks Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $2.10B.
ZYME Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 13, 2026 | Hollywood Mark | officer: EVP & Chief Operating Officer | Sell | 6,120 | $22.67 | $138.8K | 132,913 |
| Jan 12, 2026 | Galbraith Kenneth | director, officer: Chair & CEO | Sell | 60,848 | $22.67 | $1.38M | 226,842 |
| Jan 12, 2026 | Hollywood Mark | EVP & Chief Operating Officer | Sell | 6,120 | $22.67 | $138.8K | 0 |
| Jan 12, 2026 | Moore Paul Andrew | officer: Chief Scientific Officer | Sell | 19,120 | $22.67 | $433.5K | 48,497-28% |
| Jan 12, 2026 | Smith Jeffrey T L | officer: EVP & Chief Medical Officer | Sell | 18,620 | $22.67 | $422.2K | 26,708-41% |
| Jan 5, 2026 | Galbraith Kenneth | director, officer: Chair & CEO | Sell | 108,686 | $25.10 | $2.73M | 193,266-36% |
| Jan 5, 2026 | Moore Paul Andrew | officer: Chief Scientific Officer | Sell | 40,220 | $25.10 | $1.01M | 40,391-50% |
| Jan 5, 2026 | Smith Jeffrey T L | officer: EVP & Chief Medical Officer | Sell | 21,076 | $25.10 | $528.9K | 18,352-53% |
| Dec 22, 2025 | Galbraith Kenneth | Chair & CEO | Sell | 47,528 | $27.02 | $1.28M | 0 |
| Jan 21, 2025 | EcoR1 Capital, LLC | Director | Buy | 141,429 | $13.88 | $1.96M | 15,720,161 |
| Jan 15, 2025 | EcoR1 Capital, LLC | Director | Buy | 167,654 | $13.59 | $2.28M | 15,578,732 |
| Jan 10, 2025 | EcoR1 Capital, LLC | Director | Buy | 225,119 | $13.21 | $2.97M | 15,411,078 |
| Jan 6, 2025 | Galbraith Kenneth | Chair & CEO | Sell | 57,291 | $14.92 | $855.0K | 80,803-41% |
| Jan 6, 2025 | Moore Paul Andrew | Chief Scientific Officer | Sell | 21,200 | $14.92 | $316.4K | 23,333-48% |
| Jan 6, 2025 | Smith Jeffrey T L | EVP & Chief Medical Officer | Sell | 11,110 | $14.92 | $165.8K | 8,890-56% |
| Jan 2, 2025 | EcoR1 Capital, LLC | Director | Buy | 363,369 | $14.64 | $5.32M | 15,185,959 |
| Dec 27, 2024 | EcoR1 Capital, LLC | Director | Buy | 130,309 | $14.44 | $1.88M | 14,822,590 |
| Jan 8, 2024 | Astle Christopher | SVP & Chief Financial Officer | Sell | 5,994 | $10.79 | $64.7K | 7,934-43% |
| Jan 8, 2024 | Galbraith Kenneth | Chair & CEO | Sell | 23,904 | $10.79 | $257.8K | 29,468-45% |
| Jan 8, 2024 | Moore Paul Andrew | Chief Scientific Officer | Sell | 9,799 | $10.79 | $105.7K | 9,706-50% |
| Dec 11, 2023 | Astle Christopher | SVP & Chief Financial Officer | Sell | 886 | $9.13 | $8.1K | 1,997-31% |
| Jun 21, 2023 | EcoR1 Capital, LLC | 10% Owner | Buy | 3,350,000 | $8.12 | $27.20M4.5% OS | 13,437,473+33% |
| Mar 30, 2023 | EcoR1 Capital, LLC | Buy | 200,000 | $8.00 | $1.60M | 10,087,473 | |
| Mar 14, 2023 | Klompas Neil A | President & COO | Sell | 2,977 | $7.83 | $23.3K | 17,032 |
| Jan 23, 2023 | EcoR1 Capital, LLC | 10% Owner | Buy | 307,500 | $9.70 | $2.98M | 9,887,473 |
| Jan 18, 2023 | EcoR1 Capital, LLC | 10% Owner | Buy | 985,100 | $9.84 | $9.70M1.3% OS | 9,579,973 |
| Jan 12, 2023 | EcoR1 Capital, LLC | 10% Owner | Buy | 1,026,300 | $7.67 | $7.87M1.4% OS | 8,594,873 |
| Dec 14, 2022 | Astle Christopher | SVP & Chief Financial Officer | Sell | 887 | $6.01 | $5.3K | 1,333-40% |
| Nov 14, 2022 | Josephson Neil | Chief Medical Officer | Sell | 2,475 | $8.10 | $20.0K | 14,449 |
ZYME Insider Buying Activity
The following table shows recent insider purchases of Zymeworks Inc. (ZYME) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 21, 2025 | EcoR1 Capital, LLC | Director | Buy | 141,429 | $13.88 | $1.96M | 15,720,161 |
| Jan 15, 2025 | EcoR1 Capital, LLC | Director | Buy | 167,654 | $13.59 | $2.28M | 15,578,732 |
| Jan 10, 2025 | EcoR1 Capital, LLC | Director | Buy | 225,119 | $13.21 | $2.97M | 15,411,078 |
| Jan 2, 2025 | EcoR1 Capital, LLC | Director | Buy | 363,369 | $14.64 | $5.32M | 15,185,959 |
| Dec 27, 2024 | EcoR1 Capital, LLC | Director | Buy | 130,309 | $14.44 | $1.88M | 14,822,590 |
| Jun 21, 2023 | EcoR1 Capital, LLC | 10% Owner | Buy | 3,350,000 | $8.12 | $27.20M4.5% OS | 13,437,473+33% |
| Mar 30, 2023 | EcoR1 Capital, LLC | Buy | 200,000 | $8.00 | $1.60M | 10,087,473 | |
| Jan 23, 2023 | EcoR1 Capital, LLC | 10% Owner | Buy | 307,500 | $9.70 | $2.98M | 9,887,473 |
| Jan 18, 2023 | EcoR1 Capital, LLC | 10% Owner | Buy | 985,100 | $9.84 | $9.70M1.3% OS | 9,579,973 |
| Jan 12, 2023 | EcoR1 Capital, LLC | 10% Owner | Buy | 1,026,300 | $7.67 | $7.87M1.4% OS | 8,594,873 |
ZYME Insider Selling Activity
The following table shows recent insider sales of Zymeworks Inc. (ZYME) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jan 13, 2026 | Hollywood Mark | officer: EVP & Chief Operating Officer | Sell | 6,120 | $22.67 | $138.8K | 132,913 |
| Jan 12, 2026 | Galbraith Kenneth | director, officer: Chair & CEO | Sell | 60,848 | $22.67 | $1.38M | 226,842 |
| Jan 12, 2026 | Hollywood Mark | EVP & Chief Operating Officer | Sell | 6,120 | $22.67 | $138.8K | 0 |
| Jan 12, 2026 | Moore Paul Andrew | officer: Chief Scientific Officer | Sell | 19,120 | $22.67 | $433.5K | 48,497-28% |
| Jan 12, 2026 | Smith Jeffrey T L | officer: EVP & Chief Medical Officer | Sell | 18,620 | $22.67 | $422.2K | 26,708-41% |
| Jan 5, 2026 | Galbraith Kenneth | director, officer: Chair & CEO | Sell | 108,686 | $25.10 | $2.73M | 193,266-36% |
| Jan 5, 2026 | Moore Paul Andrew | officer: Chief Scientific Officer | Sell | 40,220 | $25.10 | $1.01M | 40,391-50% |
| Jan 5, 2026 | Smith Jeffrey T L | officer: EVP & Chief Medical Officer | Sell | 21,076 | $25.10 | $528.9K | 18,352-53% |
| Dec 22, 2025 | Galbraith Kenneth | Chair & CEO | Sell | 47,528 | $27.02 | $1.28M | 0 |
| Jan 6, 2025 | Galbraith Kenneth | Chair & CEO | Sell | 57,291 | $14.92 | $855.0K | 80,803-41% |
| Jan 6, 2025 | Moore Paul Andrew | Chief Scientific Officer | Sell | 21,200 | $14.92 | $316.4K | 23,333-48% |
| Jan 6, 2025 | Smith Jeffrey T L | EVP & Chief Medical Officer | Sell | 11,110 | $14.92 | $165.8K | 8,890-56% |
| Jan 8, 2024 | Astle Christopher | SVP & Chief Financial Officer | Sell | 5,994 | $10.79 | $64.7K | 7,934-43% |
| Jan 8, 2024 | Galbraith Kenneth | Chair & CEO | Sell | 23,904 | $10.79 | $257.8K | 29,468-45% |
| Jan 8, 2024 | Moore Paul Andrew | Chief Scientific Officer | Sell | 9,799 | $10.79 | $105.7K | 9,706-50% |
| Dec 11, 2023 | Astle Christopher | SVP & Chief Financial Officer | Sell | 886 | $9.13 | $8.1K | 1,997-31% |
| Mar 14, 2023 | Klompas Neil A | President & COO | Sell | 2,977 | $7.83 | $23.3K | 17,032 |
| Dec 14, 2022 | Astle Christopher | SVP & Chief Financial Officer | Sell | 887 | $6.01 | $5.3K | 1,333-40% |
| Nov 14, 2022 | Josephson Neil | Chief Medical Officer | Sell | 2,475 | $8.10 | $20.0K | 14,449 |
ZYME Insiders
Similar Stocks to ZYME
VRTX
Vertex Pharmaceuticals Incorporated
$429.47+0.81%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$734.06-1.39%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$303.44-1.64%
$41.24B
INSM
Insmed Incorporated
$135.11-0.64%
$30.79B
RVMD
Revolution Medicines, Inc.
$144.62+9.92%
$29.51B
UTHR
United Therapeutics Corporation
$566.69+0.03%
$25.13B
MRNA
Moderna, Inc.
$47.16-3.17%
$21.42B
RPRX
Royalty Pharma plc
$49.40-0.50%
$21.20B